Domestically Acquired Cyclosporiasis Cases in Multiple U.S. States, 2026 | HAN

• A study published in BMC Infectious Diseases tracking 724 US participants reveals that flu symptoms can linger for up to a month, challenging the perception of influenza as a short-lived illness. • While severe symptoms typically fade within days, the research highlights a significant period of recovery where nagging effects persist for several weeks.

• The CDC confirmed 843 cases of Cyclospora across 31 states as of July 9, 2026, while a separate, larger outbreak in Michigan has surpassed 1,562 reports. • Health officials have not yet identified a specific food source responsible for the infections, though the outbreak persists through the summer season.

• A multistate outbreak of cyclosporiasis has been identified across the United States, though the specific source of the contamination remains unknown. • Health officials are urging individuals to report all suspected cases of the parasitic infection to their local health departments to assist in tracking.

• NanoViricides has received approval from the National Ethics Committee in the Democratic Republic of Congo to conduct a Phase II trial of NV-387. • The trial will test the efficacy of NV-387 oral gummies specifically designed to treat the Bundibugyo strain of the Ebola virus.

• Oxford University has launched Phase 1 human trials for a new Ebola vaccine targeting the Bundibugyo strain, supported by CEPI. • The Serum Institute is producing over 620,000 doses, with the trial beginning just 57 days after the WHO declared the outbreak a Public Health Emergency of International Concern.

• The Oxford Vaccine Group has launched the world's first Phase I clinical trial for a vaccine targeting the Bundibugyo ebolavirus. • The initiative is being supported by India's Serum Institute to develop a viable immunization strategy against this specific strain.

• Sanofi's stock price has remained steady as of July 13, 2026, reflecting the company's stable market position within the global pharmaceutical industry. • The company's long-term growth is supported by a diversified portfolio that includes prescription medicines, vaccines, and consumer health products.

• Researchers from the University of Adelaide found that intermittent fasting is as effective for weight loss as traditional calorie restriction. • An 18-month clinical trial involving over 200 adults with obesity demonstrated that fasting requires significantly less mental effort than constant calorie counting.

• New clinical trials have been launched in the Democratic Republic of Congo to evaluate the efficacy of two drugs, MBP-134 and remdesivir, against the Bundibugyo Ebola virus. • These trials are critical because the Bundibugyo species currently lacks any approved vaccines or therapies to mitigate its spread.

• Researchers have identified new threats of flesh-eating bacteria in summer waters, coinciding with a broader decline in public health oversight. • Dr. Jha warns that the Trump administration is dismantling critical policies and incentives intended to combat the nationwide chronic disease epidemic.

• The World Health Organization (WHO) projects that new cancer cases will nearly double by 2050, with the disease currently claiming over 26,000 lives daily worldwide. • Separate research indicates that ketogenic therapy may improve both physical health and cognitive performance in patients with serious mental illnesses.